Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Favipiravir  COVID-19 treatment studies for Favipiravir  C19 studies: Favipiravir  Favipiravir   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
Evaluation of the Safety and Efficacy of Favipiravir in Adult Indian Patients with Mild-to-Moderate COVID-19 in a Real-World Setting
Reddy et al., International Journal of General Medicine, doi:10.2147/IJGM.S349241, CTRI/2020/11/029263
Reddy et al., Evaluation of the Safety and Efficacy of Favipiravir in Adult Indian Patients with Mild-to-Moderate COVID-19.., International Journal of General Medicine, doi:10.2147/IJGM.S349241, CTRI/2020/11/029263
May 2022   Source   PDF  
  All Studies   Meta
Prospective single-arm study of 1,083 patients receiving favipiravir in India, showing one death and no new safety issues.
Reddy et al., 3 May 2022, prospective, India, peer-reviewed, 19 authors, study period December 2020 - June 2021, trial CTRI/2020/11/029263.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperFavipiravirAll
Abstract: International Journal of General Medicine Dovepress open access to scientific and medical research International Journal of General Medicine For personal use only. Open Access Full Text Article C L I N I C A L T R I A L R E P O RT Evaluation of the Safety and Efficacy of Favipiravir in Adult Indian Patients with Mild-to-Moderate COVID-19 in a Real-World Setting Pavan Kumar Reddy 1 , Saiprasad Patil 2 , Akash Khobragade 3 , Akash Balki 4 , Aneesh Raj 5 , Mrunalini Kalikar 6 , Raghavendra Reddy 7 , Ravindra Shinde 8 , Jayanthi CR 9 , Abhinandan Mutha 10 , Nagaraju Boyilla 11 , Girish C Rajadhyaksha 12 , Niteen Karnik 13 , Sagar Bhagat 2 , Amol Pendse 14 , Priyanka Dhage 15 , Wen Wu 16 , Shabbir Rangwala 14 , Hanmant Barkate 2 1 Critical Care Medicine, Care Hospital, Hyderabad, Telangana, India; 2Global Medical Affairs, Glenmark Pharmaceuticals Ltd., Mumbai, Maharashtra, India; 3St. George’s Hospital, Mumbai, Maharashtra, India; 4Shree Hospital & Critical Care Center, Nagpur, Maharashtra, India; 5NIMS Medicity, Trivandrum, Kerala, India; 6Department of Pharmacology, Government Medical College, Nagpur, Maharashtra, India; 7Renova Neelima Hospitals, Hyderabad, Telangana, India; 8Respiratory Medicine, Dr Vasantrao Pawar Medical College, Nashik, Maharashtra, India; 9Bangalore Medical College, Bengaluru, Karnataka, India; 10Siddhi Hospital, Nasik, Maharashtra, India; 11Aster Prime Hospital, Hyderabad, Telangana, India; 12Department of Medicine, BYL Medical college & Nair Hospital, Mumbai, Maharashtra, India; 13Department of Medicine, LT Medical College & Sion Hospital, Mumbai, Maharashtra, India; 14Clinical Research Operations, Glenmark Pharmaceuticals Ltd., Mumbai, Maharashtra, India; 15Glenmark Pharmaceuticals Ltd., Mumbai, Maharashtra, India; 16Glenmark Pharmaceuticals Ltd., Waterford, UK Correspondence: Sagar Bhagat, Tel +919930553638, Email Purpose: To evaluate the safety and efficacy of favipiravir, which is prescribed for the treatment of patients with mild-to-moderate coronavirus disease 2019 (COVID-19) in India. Patients and Methods: This was a prospective, open-label, multicenter, single-arm postmarketing study conducted in India. Patients with mild-to-moderate COVID-19 received favipiravir (3600 mg [1800 mg orally twice daily] on the first day, followed by 800 mg orally twice daily, up to a maximum of 14 days) as a part of their treatment. The primary endpoints were to evaluate the safety of favipiravir by assessing the number of adverse events (AEs) and treatment-related AEs. The secondary endpoints were to evaluate the efficacy of favipiravir by assessing time to clinical cure, rate of clinical cure, time to pyrexia resolution, rate of oxygen requirement, and all-cause mortality. Results: A total of 1083 patients were enrolled in this study from December 2020 to June 2021. Adverse events were reported in 129 patients (11.9%), 116 (10.7%) of whom had mild AEs. Dose modification or withdrawal of favipiravir treatment was reported in four patients (0.37%). The median time to clinical cure and pyrexia resolution was 7 and 4 days, respectively. A total of 1036 patients (95.8%) exhibited clinical cure by day 14. Oxygen support was required by 15 patients (1.4%). One death was reported, which was unrelated to favipiravir. Conclusion: In the real-world setting, favipiravir was well-tolerated, and no new safety signals were detected. Keywords:..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop